A LZHEIMER DISEASE (AD) AFfects more than 4 million Americans and is one of the most frequent obstacles to healthy aging in this country. Women appear to be at higher risk for developing AD, only in part due to increased longevity.
gen by having the ability to aromatize testosterone into estrogen in the brain.
Considerable evidence has emerged from neuropathological studies, [2] [3] [4] animal behavioral studies, 5, 6 and human investigations 7, 8 to suggest that estrogen may be beneficial in improving cognition and mood in AD. Several openlabel clinical trials [9] [10] [11] and 1 randomized clinical trial 12 reported selective cognitive improvement in women with dementia who received estrogen replacement therapy (ERT). However, these studies have all been relatively brief, generally ranging from 6 to 8 weeks of treatment with estrogen. Similarly, the number of subjects taking the drug in these trials has been small, ranging from 7 to 12, and most have not used standardized diagnostic criteria. Thus, the evidence for using estrogen as treatment for clinically diagnosed AD is modest at best. Since the potential role of estrogen for the treatment of AD is of public health significance, this intervention, if scientifically supported, could become a routine part of the management regimen for women with AD.
We conducted this study to provide a definitive, placebo-controlled, doubleblind, randomized clinical trial of adequate duration and size to determine the benefit of ERT for the treatment of women with mild to moderate AD. We chose to study unopposed estrogens because previous investigations have suggested that progesterone may mitigate some of estrogen's beneficial effects in the central nervous system.
METHODS

Objectives
The specific aims of the study were to (1) determine if women with AD treated with unopposed estrogens would experience improvement or stability in cognition and other parameters during or after 12 months of therapy; (2) determine which components of the psychometric assessment were improved or stabilized by treatment; (3) determine whether there was a differential response to 2 dosages of estrogen; and (4) establish the safety and tolerability of estrogen in elderly women with AD.
Participants
Participants for this study were recruited from participating sites of the Alzheimer's Disease Cooperative Study (ADCS; a consortium supported by the National Institute on Aging), with enrollment of 120 women with hysterectomies between October 1995 and January 1999. Selection of women with hysterectomies allowed for the subjects' long-term exposure (1 year) to unopposed estrogen therapy while eliminating the risk and safety concern of endometrial hyperplasia, which occurs in prolonged unopposed estrogen administration in women with an intact uterus. Thirty-two sites (designated as AD centers by the National Institute on Aging and/or selected sites of the ADCS) participated in the recruitment of these subjects. General inclusion criteria included a diagnosis of probable AD according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria 13 in the mild to moderate stage (the study protocol specified a Mini-Mental State Examination [MMSE] 14 score of 14-28; several exceptions were made by the project director to allow for participants with MMSE scores as low as 12); female sex; previous hysterectomy (oophorectomy not required); age older than 60 years; absence of major clinical depressive disorder (as measured by scores of Ͻ17 on the Hamilton Depression Rating Scale [Ham-D] 15 ); and normal gynecological, breast, and mammography examination results.
Exclusion criteria were myocardial infarction within 1 year, history of thromboembolic disease or hypercoagulable state, hyperlipidemia, or use of excluded medications (ie, estrogens within 3 months; current use of antipsychotics, anticonvulsants, anticoagulants, ␤-blockers, narcotics, methyldopa, clonidine, or prescription cognitive-enhancing or antiparkinson medications, including experimental medications within 60 days prior to baseline. Stable dosages of neuroleptics, antidepressants, anxiolytics, sedatives, and hypnotics were allowed). At the initiation of the protocol, individuals treated with donepezil or tacrine were excluded, but a protocol amendment after 20 months of enrollment allowed the stable use (minimum of 4 weeks) of these medications before screening for the study.
Intervention
This study used a 12-month, randomized, double-blind, placebo-controlled, parallel-group design, in which 120 women were enrolled and randomized to receive a single daily dose of placebo, Premarin (conjugated equine estrogens [CEEs], Wyeth-Ayerst Pharmaceuticals, St Davids, Pa), 0.625 mg, or Premarin, 1.25 mg, followed by a 3-month, single-blind placebo washout phase for all women. Conjugated equine estrogens were chosen for this trial because this formulation is the most commonly prescribed form of ERT. Additionally, CEEs include multiple components, some of which have been shown to have neurotrophic properties, which could be beneficial to brain function.
Participants were randomly allocated to 1 of the 3 treatment arms (FIGURE 1). Treatments were assigned in randomized permuted blocks of 6 and shipped to each site at the start of the study. The ADCS biostatistical division generated and archived the randomization list. Boxes containing 7-day blister cards of study medication were packaged and shipped by the manufacturer according to instructions provided by the ADCS. Patients were instructed to take 2 identically appearing tablets of study medication each morning. Subjects assigned to estrogen, 1.25 mg/d, received 2 estrogen 0.625-mg tablets; those assigned to estrogen, 0.625 mg/d, received 1 placebo tablet and 1 estrogen 0.625-mg tablet; those assigned to placebo received 2 placebo tablets. Hereafter, the 0.625-mg/d and 1.25-mg/d estrogen dosages are referred to as low and high dosages, respectively. All subjects in this study were required to have a caregiver who administered the investigational agent during the trial. Compliance monitoring was done through plasma estradiol level evaluation at each visit and pill count.
Cognitive, global, and other outcome measures were evaluated at screening, baseline, and 2, 6, 12, and 15 months. A telephone check was performed at the 4-month interval to verify ongoing administration of the experimental medication and the status of concurrent medications and to address any issues or concerns, and a brief safety visit was conducted at the 9-month interval. The study was reviewed and approved by the institutional review board at each site. Written informed consent was obtained from all participants.
Outcome Measures
The ADCS version of the Clinical GlobalImpressionofChange(CGIC)scale,developed as a semistructured interview from the traditional CGIC scale, 16 was the primary outcome measure used to assess changefrombaseline.Onthisscale,scores of 1, 2, and 3 represent marked, moderate, and mild improvement, respectively; 4 represents no change; and 5, 6, and 7 represent mild, moderate, and marked worsening, respectively.
The MMSE (range, 0-30) and the Clinical Dementia Rating Scale 17 (CDR; range, 0-5) also were used as global staging instruments. Through the judicious choice of other secondary outcome measures, this study also aimed to address several unanswered questions: (1) independent of mood enhancement, does estrogen therapy improve cognition in AD; (2) ). Another goal in the choice of secondary measures was to assess the effect of estrogen on activities of daily living abilities in AD, as measured by the Blessed Dementia Rating Scale 28 and the Dependency Scale.
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Safety Monitoring
To reduce risk associated with estrogen administration, screening measures before enrollment included a baseline gynecological and breast examination within the 3 preceding months, a mammogram within the 6 preceding months, and a Papanicolaou test within the previous 3 years. As an additional safety measure, the mammogram was repeated at the end of the 12-month double-blind phase of the study to monitor for any breast complications. At each visit, blood pressure, body weight, and fluid retention (ankle swelling) were monitored. An additional lipid profile was performed at the 2-month visit to detect the complication of hyperlipidemia as a rare reaction to estrogen compounds. Adverse event reports were reviewed quarterly by the independent ADCS safety monitoring committee, who found no necessity to break the blind or interrupt the trial at any time.
Patient Populations
For purposes of analysis, 3 patient populations were defined. These included traditional intent-to-treat (based on a last observation carried forward imputation scheme) and completers populations (12-month visit completed) as well as a compliers population (defined as all individuals who completed the study and ingested at least 80% of the randomized agent by pill count). Of the 120 randomized subjects, 119 were exposed to the investigational agent (1 subject dropped out because of medical problems before starting the medication). Figure 1 shows the subject flow and disposition through the course of the trial. Of the 120 randomized subjects, 97 completed the trial. There was no attempt to balance the use of donepezil across treatment groups. TABLE 1 shows that more patients in the ERT groups took donepezil during the course of the trial compared with the placebo group.
Statistical Analyses
Power calculations were performed using data from a clinical trial with a similar design that included only women aged at least 60 years with baseline MMSE scores of 16 to 28. Based on the data from this similar trial, with 40 subjects receiving placebo and 80 subjects receiving estrogen, the design power was 81% to detect a 29% difference in the proportion of subjects who worsen in the 2 groups (60% worse in the placebo group vs 31% worse in the estrogen group) using a 2-tailed ␣ = .05. Since this was a dosage-finding study, a large effect size was sought to ensure clinical meaningfulness and to estimate the signal size for a possible follow-up trial, if the findings were positive. In all analyses, a set of predefined covariates was assessed as potential confounders (subject age, apolipoprotein e4 allele frequency, subject education). Any variables unbalanced at baseline (PՅ.15) and significantly associated with response (PՅ.10) were included in the statistical model. In the 2-group analysis (combined estrogen groups vs placebo group), there was no significant imbalance of the covariates at baseline, negating the inclusion of these prestated potential confounders to the statistical models. In the 3-group analysis (differential dosage response vs placebo), subject age at baseline was marginally unbalanced (P = .07) in the lowdosage estrogen group, and was significantly associated with 3 outcome variables. Therefore, age was included as a covariate in the statistical analysis models for the ADAS-Cog (P = .07), Dependency Scale (P = .07), and Grooved Pegboard (P = .06).
The primary end point used to evaluate the differential effect of estrogen on progression of AD was the ADCS-CGIC. For this analysis, the 7-point scale was collapsed to 5 points because of lack of subjects in the marked 
RESULTS
The demographic and clinical characteristics of each group at baseline are illustrated in Table 1 . No significant group differences were seen on any characteristic at baseline (all P values Ͼ.05).
Two-Group Comparison
To assess the overall efficacy of estrogen, the low-and high-dosage estrogen groups were combined into a single group of 81 women with AD and hysterectomies who took estrogen. These 81 women were compared with the 39 placebo subjects regarding performance on the ADCS-CGIC, MMSE, ADAS-Cog, and the CDR at 12 months to assess change. The primary intentto-treat analysis comparing the combined estrogen groups with the placebo group showed no difference between groups for the percentage of patients who worsened on the ADCS-CGIC (P = .48), the ADCS-CGIC score (P = .43), the MMSE score (P = .51), or the ADAS-Cog score (P = .13). However, a significant difference was seen on the CDR (P = .01) favoring the placebo group (TABLE 2 and FIGURE 2) . Repeated completers and compliers analyses on the primary outcome measure likewise did not reveal any differential treatment effects on the ADCS-CGIC (data available from the authors on request).
Analysis of secondary outcomes with sensitivity to changes in mood (Ham- Table 2) . Among the language measures, Category Fluency favored the placebo group (P = .05), yet there were no group dif- 
Three-Group Comparison
A separate analysis addressed treatment effect differences between each of the 2 dosages of estrogen compared with placebo. Again, the 12-month intentto-treat analysis showed no difference between groups for the proportion who worsened on the ADCS-CGIC (P = .73 for both low and high dosages), the ADCS-CGIC score (low dosage, P = .66; high dosage, P = .36), the MMSE score (low dosage, P = .48; high dosage, P = .64), or the ADAS-Cog score (low dosage, P = .09; high dosage, P = .32). However, a significant difference was seen on the CDR at 12 months (low dosage, P = .03; high dosage, P = .01), again favoring the placebo group (TABLE 3 and  FIGURE 3 ). In addition, we found a benefit of low-dosage estrogen on the MMSE change in score after 2 months of exposure (low dosage = −0.36; placebo = −1.64; P = .05), but the benefit did not persist with continued treatment. There was no evidence of improvement in global functioning at any point in the trial. Repeated completers and compliers analyses on the primary outcome measure likewise did not reveal any differential treatment effects on the ADCS-CGIC (data available from the authors on request).
Analysis of the remaining secondary outcome variables showed either nonsignificant differences between groups or results that favored the placebo group (Table 3) . The Ham-D, a measure of mood, did not differ between groups. The subscale factors of the MAACL-R also did not differ between groups (data available from the authors on request). There were no detectable group differences in memory, attention, or language measures. Among the motor measures, the Grooved Pegboard Test did not detect group differences, but the Finger Tapping Test again favored placebo, but only in the low-dosage group (P = .04). Measures of activities of daily living were not significantly different between groups. Repeated analyses on completer and complier populations showed the same results (data available from the authors).
Two additional analyses were performedtocompareresultsontheprimary outcome measures among women with prior estrogen exposure and then among women with prior donepezil treatment. Within each treatment group (placebo, low-dosage and high-dosage estrogen), the participants with a history of estrogen use were compared with the participants who had no history of estrogen use prior to the present trial on four 12-month outcome variables, the CGIC, CDR, MMSE and ADAS). As reflected in Table 1 , years of prior estrogen exposure were comparable between the placebo and high-dosage estrogen groups (5.4 vs 6.4 mean years). For the placebo group, mean differences on the outcome measures were not significant for prior estrogen use vs nonuse, respectively, (CGIC, 5.0 vs 5.1, P = .32; CDR, 1.3 vs 1.2, P = .42; MMSE, 18.3 vs 17.5, P = .90; ADAS-Cog, 27.9 vs 25.8, P = .41). For the high-dosage group, mean differences were likewise not significant (CGIC, 5.4 vs 5.0, P = .07; CDR, 1.7 vs 1.5, P = .24; MMSE, 16.0 vs 19.4, P = .21; ADAS-Cog, 31.4 vs 26.2, P = .97). However, participants in the low-dosage estrogen group with a longer period of prior estrogen exposure (16.8 mean years) had significantly better mean CGIC scores at 12 months (4.8 vs 5.5; P = .04), but no significant impact on the CDR (mean, 1.4 vs 1.8; P = .71), the MMSE (mean, 18.8 vs 16.4; P = .61), and the ADAS-Cog (mean, 26.6 vs 34.1; P = .86). A similar analysis of donepezil users vs nonusers showed no significant differences in performance on the CGIC, CDR, MMSE, or the ADAS-Cog outcome variables.
Treatment-emergent adverse events, grouped categorically, were not significantly different between placebo and es- trogen-treated groups. However, 2 clinically important issues arose during the trial: 4 episodes of vaginal bleeding occurred, representing protocol violations because these 4 women had not had prior hysterectomies, despite confirmatory gynecological examinations before randomization into the protocol; and 4 episodes of deep vein thrombosis occurred, 2 in the low-dosage and 2 in the high-dosage estrogen groups. Two patients died, 1 in each of the estrogen groups. Both deaths were sudden but neither death was believed to be related to treatment medication.
COMMENT
Estrogen failed to improve cognitive or functional outcomes in this 1-year study of women with mild to moderate AD and hysterectomies. Similar to previous reports, we found a benefit of lowdosage estrogen on the MMSE after brief exposure (2 months; P = .05), but the benefit did not persist with continued treatment. In fact, patients receiving estrogen appeared to decline more than those receiving placebo on 1 global clinical measure, the CDR, despite the greater use of donepezil in the estrogentreated patients. Overall, the results of this study do not support the role of estrogen in the treatment of AD.
To date, this study is the largest and the longest study to examine estrogen as a treatment for women with AD. Given that patients receiving estrogen did no better or worse than patients receiving placebo, the use of a larger sample size would not have changed this result.
There are several plausible explanations for the difference between the results of this study and previous studies. Animal studies indicate that in the neural tissue, estrogen modulates cholinergic, 3 serotonergic, 30 and catecholaminergic 31 neurotransmitter systems; regulates synaptogenesis during the estrous cycle; regulates neurogenesis 32 ; and is neuroprotective, 33 reducing the brain damage associated with ischemic insult. 34, 35 It is possible that short-term improvements that have been seen in some clinical trials were due to gene-dependent regulation of neurotransmitter systems such as the up-regulation of cholinergic activity. 36 A second mechanism of estrogen action could involve surface receptorassociated signaling via ion channels, modulating electrical properties of neurons and transmitter release processes. 37, 38 Such mechanisms are palliative, however, and insufficient to prevent decline over the long term.
In basic studies on the mechanisms underlying neurodegeneration, it has been suggested that there are at least 2 phases in the process, an initiation phase and a propagation phase. 39 It is hypothesized that estrogen can delay the initiation phase but is insufficient to slow the propagation phase. Thus, for example, cell culture studies on primary hippocampal neurons show that estrogen is only partially protective against a variety of insults. 33 Estrogen appears to operate in part through a genedependent up-regulation of antiapoptotic proteins in the bcl-2 family in vitro and in vivo. 33, 34 In the AD brain, these genes are already up-regulated and, thus, further benefit may not be gained. 40 Estrogen also has antioxidant properties, though they are relatively weak compared with vitamin E. The present data suggest that the antioxidant capacity of estrogen is evidently insufficient to slow progression. In addition, the anatomical organization of estrogen receptors may favor a role in early stages. Estrogen receptors are most concentrated in brain regions involved with the initial stages of the disease (eg, the limbic system). As degeneration spreads to other regions, estrogen might be unable to regulate gene-dependent defense mechanisms. Other mechanisms also show selectivity for the initiation and propagation phases. For example, apolipoprotein e4 appears to accelerate disease onset, but most studies agree that it does not slow the rate of progression, 39, 41, 42 although there have been exceptions. 43 While the mechanisms underlying the present results are as yet unknown, the data suggest that some therapeutic interventions may only act during selective phases of the disease process.
Thus, in the intact healthy brain, estrogen could play a key neuroprotective role by delaying the initiation phase of neurodegenerative disease onset, thereby supporting the finding of reduced risk of dementia from several published epidemiological studies. [44] [45] [46] [47] Two multicenter prevention trials are currently under way to answer this question prospectively.
Of public health concern is the tendency for experimental treatments to become standard of care before the rigorous scientific evidence is thoroughly gathered. Such is the concern with estrogen administration for women with AD. Numerous publications with broad-based distribution 48, 49 are now supporting the addition of ERT to the armamentarium of treatments for women with AD as a means to enhance cognitive function and delay progression of the disease. Such clinical practice, begun in advance of rigorous clinical trials, could prove to be detrimental to patient outcome. While other ongoing investigations (Women's Health InitiativeMemory Study, Women's International Study of Long Duration Oestrogen for Menopause, and Preventing Postmenopausal Memory Loss and Alzheimer's with Replacement Estrogens study) will provide needed data on hormone replacement therapy in the primary prevention of AD, this study does not support the role of estrogen for treatment of established AD. However, there remains a possibility that estrogen could have an important role as an adjuvant treatment, or as a means of delaying onset of disease. Further investigation of ERT in these areas is still warranted. the cap, whether in quarterly or annually capped plans, we identified the first month of the year in which the capped limit was exceeded. Unlike Rector, we were not able to identify and exclude members who disenrolled nonvoluntarily. Like Rector, we used an extended Cox model with the internally defined time-dependent variable of reaching the cap to analyze the relationship between reaching the cap and disenrollment from the health plan.
2 Models were estimated for each plan and each year controlling for participant age, sex, and chronic disease score.
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Results. The percentages of members reaching their annual prescription cap for plans A, B, and C, respectively, were 22.6%, 0.7%, and 1.6% in 1997 and 12%, 4.1%, and 3.9% in 1998. Disenrollment rates among those enrolled in the first 3 months of each year for plans A, B, and C, respectively, were 19.3%, 28.9%, and 6.8% in 1997 and 10.4%, 22.9%, and 14.0% in 1998. Among those disenrolling in 1997, 21%, 7%, and 7%, respectively, reenrolled in 1998.
The risk of disenrollment across all plans and both years was significantly associated with older age, greater disease burden (ie, higher chronic disease score), and reaching the cap. In 1997, the relative risks (RRs) of disenrollment in any given month for those reaching the cap for the 3 plans were 2.62 (95% confidence interval [ Comment. Exhaustion of prescription coverage, whether administered on a quarterly or annual basis, was associated with a 2-to 3-fold increase in the RR of disenrollment. These findings expand on those of Rector and suggest that this relationship holds under various scenarios including variation in underlying use, cap amounts, and cap administration. 
